Related Experiment Video
Updated: Nov 8, 2025
06:07
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
2.6K
First Extended-Release Injectable Drug Therapy for HIV.
1Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch : daschenbrenner@ndm.edu .
The American Journal of Nursing
|April 19, 2021
Summary
Cabenuva, an injectable HIV-1 therapy, is now approved. This complete treatment involves monthly injections after an oral regimen, offering a new option for adults.
Area of Science:
- Infectious Diseases
- Pharmacology
- Virology
Background:
- Human Immunodeficiency Virus type 1 (HIV-1) remains a significant global health challenge.
- Antiretroviral therapy (ART) is crucial for managing HIV-1 infection and preventing transmission.
- Adherence to daily oral ART can be challenging for some individuals.
Purpose of the Study:
- To announce the approval of Cabenuva, a novel injectable antiretroviral therapy for HIV-1.
- To highlight Cabenuva as the first injectable complete treatment regimen for adults with HIV-1.
- To inform healthcare providers and patients about a new long-acting treatment option for HIV-1.
Main Methods:
- Cabenuva is an injectable formulation combining two antiretroviral drugs: cabotegravir and rilpivirine.
- The treatment regimen involves an initial one-month oral lead-in period with oral cabotegravir and rilpivirine.
- Following the oral lead-in, patients receive two intramuscular injections of Cabenuva once a month.
Main Results:
- Cabenuva represents the first FDA-approved injectable therapy for the treatment of HIV-1 infection in adults.
- This formulation offers a complete treatment regimen in an injectable form.
- The administration is designed as a monthly intramuscular injection after an oral initiation phase.
Conclusions:
- The approval of Cabenuva provides a significant advancement in HIV-1 treatment options.
- Injectable therapy may improve adherence and quality of life for individuals with HIV-1.
- Cabenuva offers a new paradigm for long-acting antiretroviral therapy in adults.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
374
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
374
01:10Retrovirus Life Cycles
48.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.2K
01:24Glucagon-like Receptor Agonists
530
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
530
01:06Oral Hypoglycemic Agents: Glinides
368
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
368
01:16Insulin: Dosing Regimen and Adverse Effects
370
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
370
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
79
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
79